Simplex Trading’s Brainstorm Cell Therapeutics BCLI Stock Holding History
Bought
Maintained
Sold
Other funds holding BCLI
Simplex Trading's BCLI Position: Q4 2024 in Review
Simplex Trading sold out of Brainstorm Cell Therapeutics (BCLI) in Q4 2024, closing a stake of 77 shares.
Simplex Trading first reported a position in BCLI in Q3 2015 and held it in 25 quarters. The position peaked at $605K in Q1 2023. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.
- Simplex Trading reported no remaining Brainstorm Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
- Simplex Trading sold 77 Brainstorm Cell Therapeutics shares in Q4 2024.
- Simplex Trading first reported a position in Brainstorm Cell Therapeutics in Q3 2015 and held it in 25 quarters.
- Simplex Trading's Brainstorm Cell Therapeutics position peaked at $605K in Q1 2023.
- 34 funds tracked by Wall St. Rank held Brainstorm Cell Therapeutics as of Q4 2024.
Based on Simplex Trading's 13F filing for Q4 2024, filed 11 Feb 2025.